Peptide Therapeutics Treating Non-Small Cell Lung Cancer

The EPO published patent application EP3969121A1 as a granted patent, covering methods and compositions comprising peptide therapeutics for treating non-small cell lung cancer. The patent names John V. Heymach and Monique Nilsson as inventors and the Board of Regents of The University of Texas System as the applicant. IPC classifications span A61P (antineoplastic agents), C07K (peptides), and A61K (preparations for medical purposes), indicating a broad therapeutic composition claim scope.

For pharmaceutical manufacturers and biotech companies developing cancer therapeutics, this granted European patent establishes intellectual property protection in all designated contracting states. Companies active in NSCLC drug development should conduct freedom-to-operate analyses to assess potential overlap with this patent's claims. Universities and research institutions should similarly review the scope for overlapping research programs or potential licensing pathways.